Skip to contentN
Northwest Biotherapeutics Inc
N
NWBONorthwest Biotherapeutics Inc Q1 2026 · 10-Q
Revenue$494.00K$494.00K+31.7% vs Q1 2025 Net Income-$3.07M-$3.07MN/M vs Q1 2025 EPS Diluted$0.00$0.00N/M vs Q1 2025 Operating Income-$10,900,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Northwest Biotherapeutics Inc · CIK 1072379 · Engraved from SEC EDGAR
Free Cash Flowderived-$12,638,000N/M Margins · derivedOperating margin-2206.5%+2409.8 pt vs Q1 2025
Net margin-621.3%+4536.9 pt vs Q1 2025
ended Mar 31, 2026 · filed May 15, 2026 · 45 d after period end